{"id":"W4324132274","doi":"10.1016/s0960-9776(23)00123-6","title":"P004 Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer : a multicenter, open-label, phase 2 trial","year":2023,"lang":"en","type":"article","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Medicine; Trastuzumab; Open label; Oncology; Adjuvant; Breast cancer; Internal medicine; Adjuvant therapy; Clinical trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006875239,0.0003497575,0.0005531557,0.0002139803,0.000127931,0.0001068689,0.0005463847,0.000100513,0.001098006],"category_scores_gemma":[0.00002633944,0.0002101142,0.00006901212,0.0009921237,0.0002745666,0.0001624689,0.0001563918,0.0005458721,0.000147549],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004902542,"about_ca_system_score_gemma":0.0007885969,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002085407,"about_ca_topic_score_gemma":0.0005245942,"domain_scores_codex":[0.9969462,0.0003429361,0.0003840215,0.0005799853,0.0009464143,0.0008004785],"domain_scores_gemma":[0.9984927,0.0001720816,0.0001202831,0.000666326,0.0002768982,0.0002717592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6766312,0.009649857,0.1144632,0.0000891168,0.0002883851,0.0002625784,0.001825768,0.00002871013,0.0003325153,0.000004013367,0.00283622,0.1935884],"study_design_scores_gemma":[0.3849675,0.004540281,0.6071829,0.001045739,0.00006668635,0.00002368227,0.0001848373,0.0008368565,0.0003040338,0.00000592733,0.0005409787,0.000300582],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853463,0.0001062095,0.00000793748,0.006735173,0.0002411682,0.005799182,0.001397443,0.00009499215,0.0002715914],"genre_scores_gemma":[0.9956852,0.00006036369,0.00003663145,0.001178261,0.0003096202,0.001983523,0.0001678652,0.0001083805,0.0004701842],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4927197,"threshold_uncertainty_score":0.9998151,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04864517656838026,"score_gpt":0.3922865478377956,"score_spread":0.3436413712694154,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}